*Title of the project:* Difference in the behavior of the freshly isolated and cryo-preserved ovarian cancer cells and its clinical significance

Grant Agency: Ministry of Health Project Number: NR/8768-3/06

Principal Investigator: J. Tošner

*Co-investigators:* I. Sedláková, M. Kudela, M. Červinka, O. Kopecký, M. Tomšová, J. Špaček, M. Hajdúch, R. Pilka, P. Měřička

Starting date: 1.3.2006 Duration (years): 4

Total funds allocated for project - Kč (thousands): 3412

## Summary of 2007 results

*Title of the presentation:* Difference in the behavior of the freshly isolated and cryopreserved ovarian cancer cells and its clinical significance

Authors: J. Tošner (1), I. Sedláková (2), M. Kudela (3), M.Červinka(1), O.Kopecký (2), P.Měřička (2), M.Tomšová (2), J. Špaček (1), M.Hajdúch (3), R. Pilka (3),

- (1) Charles University in Prague, Faculty of Medicine Hradec Králové
- (2)University Hospital Hradec Králové
- (3)University Hospital Olomouc

One of the major goals of oncology is to predict the response of patients with cancer to chemotherapeutic agents by employing laboratory methods called tumour chemosensitivity assays.

The aim of the project is to evaluate usefulness of the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrazolium bromide chemosensitivity test (MTT test). Assessment of results obtained from fresh and defrost tumor tissue is of essential importance for chemoresistance testing in practice as frozen samples could be transported to specialized laboratory from whole republic.

During the year 2007 (second year of project) cells from solid tumours of 18 patients were tested in Hradec Králové and 14 samples from ascites. Cooworkers in Olomouc have tested, 26 samples from tumours and 13 from ascites. 12 tumors were frost by special procedure in Tissue Bank of University Hospital. VEGF and CA125 were investigated in 30 patients as well as phenotyping. 39 patients were investigated for LRP at ht Departement of Pathology Tumour infiltrating lymphocytes and tumor markers were investigated in all patients with ascites.

Fresh tumor tissue samples were tested mainly against cisplatinum, paclitaxel, carboplatinum, doxorubicin, gemcitabin, docetaxel and topotecan.

Previous results are expected at the end of the year 2008.

Address for correspondence: J.Tošner, Dept.of Gynecology and Obstetrics, Charles University in Prague, Faculty of Medicine Hradec Králové, Nova nemocnice, Sokolska 581, 50005 Hradec Kralové, Czechia E-mail tosner@fnhk.cz